Page 133 - 2021年18期

Cancer Res，2018，211：57-65. [41] DRILON A，LAETSCH T W，KUMMAR S，et al. Efficacy
[31] DRILON A，BARLESI F，BRAUD F D，et al. Abstract of larotrectinib in TRK fusion-positive cancers in adults
CT192：entrectinib in locally advanced or metastatic ROS1 and children[J]. N Engl J Med，2018，378（8）：731-739.
fusion-positive non-small cell lung cancer（NSCLC）：inte- [42] DRILON A. TRK inhibitors in TRK fusion-positive can-
grated analysis of ALKA-372-001，STARTRK-1 and cers[J]. Ann Oncol，2019，30（Suppl 8）：viii23-viii30.
STARTRK-2[C]//Atlanta，GA：AACR Annual Meeting， [43] HYMAN D，KUMMAR S，FARAGO A，et al. Abstract
2019. CT127：phase Ⅰ and expanded access experience of
[32] SHAW A T，RIELY G J，BANG Y J，et al. Crizotinib in LOXO-195（BAY 2731954），a selective next-generation
ROS1-rearranged advanced non-small-cell lung cancer TRK inhibitor（TRKi）[C]//Atlanta，GA：AACR Annual
（NSCLC）：updated results，including overall survival， Meeting，2019.
from PROFILE 1001[J]. Ann Oncol，2019，30（7）：1121- [44] DRILON A，OU S I，CHO B C，et al. Repotrectinib
1126. （TPX-0005）is a next-generation ROS1/TRK/ALK inhibi-
[33] LIM S M，KIM H R，LEE J S，et al. Open-Label，Multi- tor that potently inhibits ROS1/TRK/ALK solvent-front
center，phase Ⅱ study of ceritinib in patients with mutations[J]. Cancer Discov，2018，8（10）：1227-1236.
non-small-cell lung cancer harboring ROS1 rearrange- [45] DRILON A，KUMMAR S，MORENO V，et al. Activity of
ment[J]. J Clin Oncol，2017，35（23）：2613-2618.
larotrectinib in TRK fusion lung cancer[J]. Ann Oncol，
[34] SYED Y Y. Lorlatinib：first global approval[J]. Drugs，
2019，30（Supplement_2）：ii43-ii44.
2019，79（1）：93-98. [46] JIN W. Roles of TRKC signaling in the regulation of tu-
[35] CHO B C，DRILON A E，DOEBELE R C，et al. Safety
morigenicity and metastasis of cancer[J]. Cancers，2020，
and preliminary clinical activity of repotrectinib in pa-
12（1）：147.
tients with advanced ROS1 fusion-positive non-small cell
[47] MARCHIÒ C，SCALTRITI M，LADANYI M，et al.
lung cancer（TRIDENT-1 study）[J]. J Clin Oncol，2019，37
ESMO recommendations on the standard methods to detect
（15_suppl）：9011. NTRK fusions in daily practice and clinical research[J].
[36] COSTA D B，KOBAYASHI S，PANDYA S S，et al. CSF
Ann Oncol，2019，30（9）：1417-1427.
concentration of the anaplastic lymphoma kinase inhibitor
[48] FACCHINETTI F，ROSSI G，BRIA E，et al. Oncogene ad-
crizotinib[J]. J Clin Oncol，2011，29（15）：443-445.
diction in non-small cell lung cancer：focus on ROS1 inhi-
[37] TEJAS P，SMITH D E，BUNN P A，et al. The incidence
bition[J]. Cancer Treat Rev，2017，55：83-95.
of brain metastases in stage Ⅳ ROS1-rearranged
[49] KU B M，BAE Y H，LEE K Y，et al. Entrectinib resistance
non-small cell lung cancer and rate of central nervous sys-
mechanisms in ROS1-rearranged non-small cell lung can-
tem progression on crizotinib[J]. J Thorac Oncol，2018，13
cer[J]. Invest New Drugs，2020，38（2）：360-368.
（11）：1717-1726.
[38] SIENA S，DOEBELE R C，SHAW A T，et al. Efficacy of [50] GAINOR J F，TSENG D，YODA S，et al. Patterns of meta-
entrectinib in patients（PTS）with solid tumors and central static spread and mechanisms of resistance to crizotinib in
nervous system（CNS）metastases：Integrated analysis ROS1-positive non-small-cell lung cancer[J]. JCO Precis
from three clinical trials[J]. J Clin Oncol，2019，37（15_ Oncol，2017（1）：1-13.
suppl）：3017. [51] FACCHINETTI F，FRIBOULET L. Profile of entrectinib
[39] DAGOGO-JACK I，SHAW A T. Expanding the roster of and its potential in the treatment of ROS1-positive
ROS1 inhibitors[J]. J Clin Oncol，2017，35（23）：2595- NSCLC：evidence to date[J]. Lung Cancer（Auckl），2019，
2597. 10：87-94.
[40] DEMETRI G D，PAZ-ARES L，FARAGO A F，et al. [52] KATAYAMA R，GONG B，TOGASHI N，et al. The
LBA4Efficacy and safety of entrectinib in patients with new-generation selective ROS1/NTRK inhibitor DS-6051b
NTRK fusion-positive tumours： pooled analysis of overcomes crizotinib resistant ROS1-G2032R mutation in
STARTRK-2，STARTRK-1，and ALKA-372-001[J/OL]. preclinical models[J]. Nat Commun，2019，10（1）：3604.
Ann Oncol，2018，29（suppl_9）[2021-03-12]. http：//doi. （收稿日期2021-03-12 修回日期2021-08-18）
org/10.1093/anonc/mdy483.003. （编辑：邹丽娟）

中国药房 2021年第32卷第18期 China Pharmacy 2021 Vol. 32 No. 18 ·2299 ·